KOSDAQBiotech & Pharma284620

Kainos Medicine

₩1,087 0.00%2026-11-18 close
Market Cap
₩36B
Turnover
₩0
Volume
0 shares
Shares out.
33.1M
PER
—
PBR
—
EPS
-₩165
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Royalty growth amid listing and capital-impairment overhang

Kainos Medicine's revenue rose for three straight years through 2025 and its losses narrowed, but a KOSDAQ delisting decision from January 2026 remains suspended pending a court injunction, and the 2026 half-year report showed full capital impairment and a rejected review opinion.

  1. 1

    On a DART-filed basis, revenue grew from KRW 130 million in 2022 to KRW 1.17 billion in 2025, with royalty income cited as the main driver.

  2. 2

    Operating loss narrowed from KRW 16.2 billion in 2022 to KRW 6.44 billion in 2025, yet the company has recorded losses for four consecutive years.

  3. 3

    The KOSDAQ Market Committee resolved on January 13, 2026 to delist the shares, and a court injunction filed the next day has put the delisting procedures on hold.

  4. 4

    The 2026 half-year statements carried a rejected review opinion and full capital impairment, and on August 14, 2026 the company disclosed added grounds for investment-caution designation and a listing-qualification review.

  5. 5

    The lead pipeline asset KM-819 has been without an active Phase 2 trial since its August 2024 suspension; the company has outlined a restart plan, but timing and funding are not yet fixed.

02

Business structure

Kainos Medicine is a drug developer founded in 2007 that listed on KOSDAQ in June 2020 through a SPAC merger.

Its lead pipeline asset is KM-819, a candidate for multiple system atrophy (MSA) and Parkinson's disease that works by inhibiting the FAF1 protein; the Phase 2 trial in Korea was voluntarily halted in August 2024 and the company is preparing a restart.

Its current revenue base is royalty income from the KM-023 franchise, an AIDS treatment whose China rights were licensed to a Chinese partner in exchange for a 2% royalty on that partner's product sales.

The company said royalty revenue has risen every year since a single-tablet formulation (ACC008) was listed on China's national health insurance at the end of 2023, and royalty growth is cited as the main reason revenue increased.

Because royalties come mainly from China, sales depend heavily on that partner's performance and on new indication approvals. The neuro pipeline and the antiviral royalty business carry very different economics and risks, so they should be read separately.

At the March 31, 2026 annual general meeting, the re-election of CEO Lee Ki-seop as an inside director and the approval of the 2025 financial statements were both passed as proposed, and the board has three directors, one of them independent. The head office is located in Bundang-gu, Seongnam-si, Gyeonggi-do.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩300M-₩1.5B−467.3%
2025Q4₩300M-₩2.3B−755.8%
2026Q1₩400M-₩1B−273.2%
2026Q2₩400M-₩1.1B−258.1%
2026Q3₩400M-₩600M−144.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩100M-₩16.2B-₩15.9B−12425.1%−60.8%30.3%
2023₩300M-₩16.8B-₩15.2B−6289.1%−129.6%33.1%
2024₩600M-₩12.3B-₩12.2B−2088.2%−681.8%82.9%
2025₩1.2B-₩6.4B-₩7.8B−549.6%−678.7%43.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a DART-filed basis, annual revenue went from KRW 130 million in 2022 to KRW 267 million in 2023 (up 105.6% year on year), KRW 590 million in 2024 (up 120.9%) and KRW 1.17 billion in 2025 (up 98.5%).

Revenue has grown for three consecutive years from 2023 to 2025, and 2025 is the largest year of the 2022 to 2025 period.

Operating loss was KRW 16.2 billion in 2022, KRW 16.8 billion in 2023 (loss widened), KRW 12.3 billion in 2024 and KRW 6.44 billion in 2025 (loss narrowed), so the company has been loss-making for four consecutive years.

Operating margin moved from -12,425.1% in 2022 to -6,289.1% in 2023, -2,088.2% in 2024 and -549.6% in 2025, but with revenue this small the ratio is highly sensitive to the revenue base.

Net loss attributable to controlling shareholders was KRW 15.9 billion in 2022, KRW 15.2 billion in 2023, KRW 12.2 billion in 2024 and KRW 7.78 billion in 2025, a loss in each of the four years with the loss narrowing in 2024 and 2025.

Net loss including non-controlling interests is reported at the same amounts in each year, so the two figures match in this period. Operating cash outflow fell from KRW 11.3 billion in 2022 and KRW 14.2 billion in 2023 to KRW 9.71 billion in 2024 and KRW 5.92 billion in 2025.

Quarterly revenue was KRW 322 million in the third quarter of 2025, KRW 304 million in the fourth quarter (down 5.6% from the prior quarter), KRW 370 million in the first quarter of 2026 (up 21.8%), KRW 408 million in the second quarter (up 10.2%) and KRW 402 million in the third quarter of 2026 (down 1.5% from the prior quarter but up 24.8% year on year).

Operating loss widened from KRW 1.51 billion in the third quarter of 2025 to KRW 2.3 billion in the fourth quarter, then narrowed to KRW 1.01 billion, KRW 1.05 billion and KRW 582 million over the next three quarters, and the company has reported operating losses in five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.

Net loss attributable to controlling shareholders in the third quarter of 2026 was KRW 928 million, the smallest of the five quarters, and the four quarters from the fourth quarter of 2025 to the third quarter of 2026 total KRW 5.42 billion.

The company attributed part of the narrowing to higher royalty revenue and lower costs after the domestic MSA Phase 2 trial was halted.

05

Industry analysis

Drug developers typically earn money in one of two ways: licensing technology for royalties or milestones, or raising outside capital to fund clinical trials whose outcomes are uncertain. Kainos Medicine relies on KM-023 royalties for its revenue base, while the funds needed for the KM-819 trials have not been secured.

KOSDAQ listing requirements cover equity, revenue, audit opinion and capital impairment, and in the first half of 2025 the company's revenue fell short of the semiannual revenue threshold of KRW 700 million. In the 2026 half-year report, full capital impairment and a rejected audit opinion were confirmed.

The Korea Exchange said its January 2026 delisting decision reflected an overall assessment of business continuity and management transparency. Clinical suspension, capital impairment and an accumulated loss-related test on pre-tax losses together formed the core of the exchange's view.

When comparing with listed peers in biopharma, the relevant benchmarks are whether a company combines clinical-stage pipelines with royalty income and whether its trial restart timelines are clear.

On both counts Kainos Medicine differs widely from that benchmark, with small royalty income and an uncertain restart schedule. The link between pipeline outcomes and access to funding is a general feature across the drug development sector.

06

Outlook

The nearest business milestone the company has described is the restart of the MSA Phase 2 trial for KM-819. After the August 2024 suspension, the company said it analyzed the cause of the adverse reactions and planned to submit an IND and resume the domestic Phase 2 trial.

The restart timing and trial design have not been fixed as a confirmed schedule. The company has also said it plans a US trial after the restart and has targeted orphan drug designation and conditional marketing approval through fast-track in 2028.

For Parkinson's disease, the company previously estimated that about USD 30 million in clinical costs would be needed.

On funding, a third-party share issue of about KRW 14.5 billion announced in December 2025 was withdrawn on January 23, 2026 after the subscriber failed to pay, leaving the new-capital route unresolved.

For KM-023, the company has said new indication approval in China could lift share there, and that it aims to expand supply to the United States and Europe. The next items to watch are the court's ruling on the injunction and the follow-up steps by the Korea Exchange, which will determine the company's listing status.

The audit opinion in the 2026 annual report and whether capital impairment is resolved are also key checkpoints. Whether the narrowing operating loss of KRW 582 million in the third quarter of 2026 carries into the full-year results is a further point to follow.

07

Valuation

PER
—
PBR
—
ROE
-472.2%
EPS
-₩165
BPS
—
Dividend per share
₩0

The current price-to-earnings ratio cannot be calculated because the company has posted net losses over the last four quarters, and the company does not pay dividends.

Market capitalization sits far above consolidated total equity at the end of 2025, and the gap is wider against the equity attributable to controlling shareholders. With capital impaired, asset-based multiples offer limited guidance on the share price.

Because no earnings-based multiple exists, comparisons with industry averages remain factual rather than conclusive. How the market value is anchored depends on whether royalty income is seen as durable, how likely a trial restart is, and how much weight the listing status receives.

With trading procedures on hold after the delisting decision, the market value reading depends heavily on the court ruling and the exchange's follow-up steps. Press reports put the capital impairment ratio at 93.1% based on the 2025 year-end settlement. The starting point for valuation here is the listing status rather than the price level.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Consecutive growth in royalty-based revenue

Royalties from the KM-023 franchise lifted revenue from KRW 130 million in 2022 to KRW 1.17 billion in 2025, with growth in each year since 2023. The company said royalty revenue has risen annually since the single-tablet formulation was listed on China's health insurance at the end of 2023.

Third-quarter 2026 revenue of KRW 402 million was up 24.8% from a year earlier, so the growth trend has continued.

Lower costs and a narrowing loss

Operating loss narrowed from KRW 12.3 billion in 2024 to KRW 6.44 billion in 2025, and the KRW 582 million loss in the third quarter of 2026 is the smallest quarterly operating loss in the reported five-quarter window.

The company said lower costs after the domestic MSA Phase 2 halt were partly reflected in the narrowing. Operating cash outflow also declined from KRW 9.71 billion in 2024 to KRW 5.92 billion in 2025.

Plans to resume the pipeline

The company has said it intends to continue the MSA Phase 2 program for KM-819 and the Parkinson's disease indication. At an earlier press briefing it set a target of orphan designation and conditional approval through fast-track in 2028.

The restart timing and clinical outcome are not yet fixed, so this remains a plan rather than a confirmed development.

09

Bear factors

Rejected audit opinion and full capital impairment

The consolidated financial statements for fiscal 2025 carried a disclaimer of opinion, and the 2026 half-year report also received a rejected review opinion. Full capital impairment was confirmed at the 2026 half-year end, which added a listing-qualification review ground on August 14, 2026. Press reports put the capital impairment ratio at 93.1% based on the 2025 year-end settlement.

Delisting decision and suspended procedures

The KOSDAQ Market Committee resolved to delist the shares on January 13, 2026, and the company filed an injunction application with the Seoul Southern District Court the following day. Delisting procedures, including the clearing sale, remain on hold until the court rules, so the outcome is still open.

A third-party share issue worth about KRW 14.5 billion was withdrawn on January 23, 2026, which narrowed the funding route.

Clinical suspension and financial strain

KM-819's domestic Phase 2 was halted in August 2024 after liver-related adverse reactions were reported in 10 of 61 enrolled patients. The company previously estimated the MSA trial would cost roughly KRW 21 billion to 28 billion. The pre-tax loss ratio against equity was 53.2% in 2022, 96.6% in 2023 and 207.5% in 2024, all above 50%.

10

Risk factors

Listing-status risk

The listing status will depend on the court's ruling on the injunction, with follow-up procedures by the exchange to come after that decision. The exchange has said it will proceed with follow-up steps once the court rules.

The first-half 2025 revenue shortfall against the listing threshold and the full capital impairment at the 2026 half-year end remain financial factors in that assessment.

Funding risk

Total liabilities were KRW 2.01 billion at the end of 2025 and total equity was KRW 4.6 billion, but equity attributable to controlling shareholders was only KRW 1.15 billion. With the KRW 14.5 billion share issue withdrawn, the route to funding the trial restart is uncertain.

Even with narrower losses, the four quarters to the third quarter of 2026 total KRW 5.42 billion in net losses attributable to controlling shareholders, so reliance on outside funding remains.

Clinical and regulatory risk

KM-819 has a history of suspension over liver-related adverse reactions, so safety data after any restart will be a central variable. The restart timing, a planned US trial and the conditional approval target all depend on securing funds and on regulatory judgment. If funding is delayed, the schedule the company has outlined could slip further.

11

What to watch next

  1. Date TBD (after the injunction ruling)

    The Seoul Southern District Court's ruling on the injunction. Depending on the outcome, the clearing sale and other delisting steps may resume, and the exchange's listing-qualification review will follow.

  2. Late March 2027 (filing deadline for the 2026 annual report)

    The audit opinion for fiscal 2026, full-year results and whether capital impairment is resolved. It will show whether the narrowing in the third-quarter 2026 operating loss of KRW 582 million carries through the year.

  3. Date TBD (when the trial restart is announced)

    Approval to resume the MSA Phase 2 trial for KM-819 and the related funding plan. Whether the restart timetable and funding method become firm is the turning point for pipeline progress.

  4. Date TBD (when new financing is disclosed)

    Any new equity financing disclosure. The key questions are whether actual payment is completed, unlike the share issue withdrawn in January 2026, and who the subscribers are.

12

Overall view

Kainos Medicine's revenue rose from KRW 130 million in 2022 to KRW 1.17 billion in 2025, growing for three consecutive years, while operating and net losses narrowed in 2024 and 2025. Royalty-based revenue and lower costs after the clinical halt are the factors the company cites for the narrowing.

However, a delisting was resolved on January 13, 2026, and the procedures remain suspended until the court rules on the injunction. The 2026 half-year statements carried a rejected review opinion and full capital impairment, and a listing-qualification review ground was added on August 14, 2026.

The lead pipeline asset KM-819 has no confirmed restart date after its 2024 suspension, and the withdrawal of the January 2026 share issue leaves its funding route uncertain. The third-quarter 2026 operating loss of KRW 582 million and the four-quarter net loss total of KRW 5.42 billion show losses getting smaller.

The items to watch first are the injunction outcome, the exchange's follow-up steps and the audit opinion in the 2026 annual report. This report does not include a buy or sell opinion or a target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. thevc.kr
  3. topstarnews.net
  4. m.dailypharm.com
  5. m.healthcaren.com
  6. goinsider.kr
  7. news.dealsitetv.com
  8. pharm.edaily.co.kr
  9. pharm.edaily.co.kr
  10. vegannews.co.kr
  11. topstarnews.net
  12. news.nate.com
  13. m.news.nate.com
  14. cbci.co.kr
  15. news.nate.com
  16. v.daum.net
  17. view.asiae.co.kr
  18. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis